ArticleJournal of neuroimmunology2008
Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis.
Article in Journal of neuroimmunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells.Journal of clinical immunology · 2010Trial
- Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis.The Journal of clinical investigation · 2024Article
- Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.International journal of molecular sciences · 2021Review
- Immune-mediated genesis of multiple sclerosis.Journal of translational autoimmunity · 2020Review
- Complement and the Regulation of T Cell Responses.Annual review of immunology · 2018Review
- Complement as a regulator of adaptive immunity.Seminars in immunopathology · 2018Review
- Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Dendritic cells as therapeutic targets in neuroinflammation.Cellular and molecular life sciences : CMLS · 2016Review
- Role and therapeutic value of dendritic cells in central nervous system autoimmunity.Cell death and differentiation · 2015Review
- Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.Mediators of inflammation · 2015Review
- Next-generation sequencing identifies microRNAs that associate with pathogenic autoimmune neuroinflammation in rats.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Possible role of human herpesvirus 6 as a trigger of autoimmune disease.TheScientificWorldJournal · 2013Review
- Prostaglandin E2 affects T cell responses through modulation of CD46 expression.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- CD46 processing: a means of expression.Immunobiology · 2012Review
- CD46 in innate and adaptive immunity: an update.Clinical and experimental immunology · 2011Review
- CD46 plasticity and its inflammatory bias in multiple sclerosis.Archivum immunologiae et therapiae experimentalis · 2011Review
- The dynamic processing of CD46 intracellular domains provides a molecular rheostat for T cell activation.PloS one · 2011Article
- Complement: a key system for immune surveillance and homeostasis.Nature immunology · 2010Review
- Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2010Article
- Role of the innate immune system in the pathogenesis of multiple sclerosis.Journal of neuroimmunology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). In MS, myeloid dendritic cells (mDCs) secrete elevated amounts of IL-23, a potent proinflammatory cytokine, compared to healthy donors. Here, we examined the role of CD46, a complement binding factor, in mDCs by analyzing cytokine and chemokine production in healthy donors and patients with MS. There were striking differences between these groups with increased IL-23p19, CCL3 and CCL5 production, but decreased CCL2 levels in patients. This demonstrates major differences of DC activation upon CD46 activation, with a potential role in the pathogenesis of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.